Author:
Johnson-Davis Kamisha L.,Thomas Ronald L.
Reference16 articles.
1. Novartis Trileptal package insert. https://www.bing.com/ck/a?!&&p=4afe3dea94aea530JmltdHM9MTY3NzQ1NjAwMCZpZ3VpZD0yNDQ4YWVlOS01NjA1LTY0MDYtMjUyZi1iZjFkNTIwNTZhNDEmaW5zaWQ9NTE5NA&ptn=3&hsh=3&fclid=2448aee9-5605-6406-252f-bf1d52056a41&psq=oxcarbazepine+package+insert&u=a1aHR0cHM6Ly93d3cuYWNjZXNzZGF0YS5mZGEuZ292L2RydWdzYXRmZGFfZG9jcy9sYWJlbC8yMDA5LzAyMTAxNHMwMjYsMDIxMjg1czAyMWxibC5wZGY&ntb=1. Accessed 27 Feb 2023
2. Patsalos PN, Berry DJ, Bourgeois BF, Cloyd JC, Glauser TA, Johannessen SI, Leppik IE, Tomson T, Perucca E (2008) Antiepileptic drugs--best practice guidelines for therapeutic drug monitoring: a position paper by the subcommission on therapeutic drug monitoring, ILAE Commission on Therapeutic Strategies. Epilepsia 49(7):1239–1276. https://doi.org/10.1111/j.1528-1167.2008.01561.x
3. ARK™ Oxcarbazepine Metabolite Assay (Trileptal®). https://www.ark-tdm.com/products/epilepsy/oxcarbazepine/index.html#:~:text=The%20ARK%E2%84%A2%20Oxcarbazepine%20Metabolite%20Assay%20is%20intended%20for,of%20oxcarbazepine%20metabolite%20to%20help%20ensure%20appropriate%20therapy. Accessed 2 Mar 2023
4. Begas E, Tsakalof A, Dardiotis E, Vatidis GE, Kouvaras E, Asprodini EK (2017) Development and validation of a reversed-phase HPLC method for licarbazepine monitoring in serum of patients under oxcarbazepine treatment. Biomed Chromatogr 31(9):e3950. https://doi.org/10.1002/bmc.3950
5. Fortuna A, Sousa J, Alves G, Falcão A, Soares-da-Silva P (2010) Development and validation of an HPLC-UV method for the simultaneous quantification of carbamazepine, oxcarbazepine, eslicarbazepine acetate and their main metabolites in human plasma. Anal Bioanal Chem 397(4):1605–1615. https://doi.org/10.1007/s00216-010-3673-0